key: cord-0801523-fp1ufmrx
authors: Wang, Liqin; Foer, Dinah; Bates, David W.; Boyce, Joshua A.; Zhou, Li
title: Risk factors for hospitalization, intensive care and mortality among patients with asthma and COVID-19
date: 2020-07-29
journal: J Allergy Clin Immunol
DOI: 10.1016/j.jaci.2020.07.018
sha: beb03c8e157ad6600c043dd82aae3b1c25e9ed17
doc_id: 801523
cord_uid: fp1ufmrx

Capsule summary: This study describes the presenting characteristics of patients with asthma and COVID-19 in a US health care system, establishing an evidence base for risk evaluation and clinical care for asthma during the COVID-19 pandemic.

Funding sources: L.W., D.W.B and L.Z. are supported by NIH-NIAID R01AI150295 and AHRQ 24 R01HS025375. D.F. is supported by NIH-T32AI007306. J.A.B. is supported by NIH-NIAID 25 R01AI078908, R01AI136041, R37AI052353, U19AI095219, and NIH-NHLBI R01HL117945. 26

Disclosures: L.W, D.F. and L.Z. report no disclosures. D.W.B consults for EarlySense, which 27 makes patient safety monitoring systems. He receives cash compensation from CDI (Negev), 28

Ltd, which is a not-for-profit incubator for health IT startups. He receives equity from 29

ValeraHealth which makes software to help patients with chronic diseases; equity from Clew, 30 which makes software to support clinical decision-making in intensive care; equity from 31

MDClone which takes clinical data and produces deidentified versions of it; equity from AESOP 32 which makes software to reduce medication error rates. He will be receiving research funding Respiratory viral illnesses are a well-established trigger of asthma exacerbations in 43 children and adults 1 and risk factor for poor outcomes and high healthcare utilization 2 . Early 44 studies from China identified chronic pulmonary disease as a risk factor 3 for novel coronavirus 45 disease 2019 (COVID-19) severity 4 and death 5 . US-based studies report approximately 7-9% of 46 hospitalized COVID-19 patients had chronic lung disease 6,7 with asthma more prevalent than chronic obstructive pulmonary disease (COPD) (9% versus 5.4% respectively) 7 . Recent 48 analyses of COVID-19 cohorts suggest that chronic respiratory disease may unexpectedly be 49 less of a risk factor for COVID-19 infection and severity than non-respiratory diseases 8 . 50

However, most studies to date do not distinguish asthma from COPD within chronic respiratory 51 disease, limiting identification of asthma-specific risk factors 9 . 52

This case series used data (March 3, 2020 -June 8, 2020) from the Massachusetts-53 based Mass General Brigham (MGB, formerly Partners HealthCare) health system's electronic 54 health record (EHR). Inclusion criteria were: 1) COVID-19 positive based on nasopharyngeal or 55 sputum SARS-CoV-2 reverse transcriptase-PCR test administered between March 3, 2020 and 56 May 20, 2020; 2) age ≥18 years at COVID-19 diagnosis; 3) previously diagnosed asthma, 57 assessed as active asthma diagnosis on problem list or two or more separate encounters with 58

International Classification of Diseases (ICD)-9 and/or ICD-10 codes (detailed in the Online 59 Supplement Table E1 ) as a primary or secondary diagnosis; and 4) MGB primary care provider. 60

Demographics, socioeconomic markers, baseline body mass index (BMI), insurance, smoking 61 status, baseline outpatient-prescribed asthma medications, comorbidities including allergic and 62 respiratory diseases and clinical course of COVID-19 care were extracted. Patients' encounter 63 history was followed for 14 days from COVID-19 diagnosis for hospitalization and intensive care 64 unit (ICU) admission, or by June 8, 2020 for mortality. 65

We examined associations of demographic and clinical characteristics with 66 hospitalization and ICU admission among those hospitalized for COVID-19, and mortality. 67

Groups were compared using the Mann-Whitney-Wilcoxon test for continuous variables and chi-68 square test or Fisher's exact test for categorical variables. Unadjusted P-value ≤.1 was used as 69 a cutoff for choosing variables to enter into subsequent risk factor analysis. We performed 70 univariable and multivariable analysis using age-stratified logistic regression. Statistical significance was accepted at a two-sided P-value of ≤.05. A Bonferroni-corrected P <.0016 was 72 used to adjust for multiple testing. Statistical analyses were performed in R software, version 73

A total of 1,827 patients met inclusion criteria ( Compared to the outpatient group, hospitalized patients had higher baseline use of 86 inhaled-corticosteroid long acting-beta agonist (ICS-LABA) combination and anti-cholinergic 87 controller medications. Controller medication use did not differ in the hospitalized general 88 inpatient vs ICU groups. More patients in the outpatient group had only a short acting beta 89 agonist (SABA) prescribed in the prior year compared to hospitalized patients (P <.001) while a 90 higher percentage of hospitalized patients had been prescribed combined SABA-anticholinergic 91 reliever medications (P <.001) ( Table 1 ). 54.7% of patients prescribed SABA-anticholinergic 92 relievers were also prescribed a controller medication. Only baseline SABA medications differed 93 between general inpatient and ICU patients (P = .024). Patients receiving biologics for asthma 94 therapy did not differ across groups (Table E3) .

Increased risk for hospitalization versus outpatient care was significantly associated 96 (Table 2) with older age (unadjusted OR, 1.46; 95% CI, 1.38-1.55; P <.001, for every increase 97 of 10 years), male sex (adjusted odds ratio [aOR], 1.75; 95% CI, 1.36-2.24; P <.001), Black 98 (aOR, 1.65; 95% CI, 1.19-2.27; P =.002) and Asian race (aOR, 3.19; 95% CI, 1.56-6.54; P 99 =.0015), diabetes mellitus (aOR, 1.33; 95% CI, 1.0-1.75; P <.05), co-morbid COPD (aOR, 1.92; 100 95% CI, 1.35-2.72; P <.001), cardiovascular disease (aOR, 1.52; 95% CI, 1.16-2.0; P =.002), or 101 with an active outpatient prescription for combined SABA-anticholinergic medication (aOR, 1.74; 102 95% CI, 1.09-2.8; P <.05). Sixty-two percent of hospitalized SABA-anticholinergic users also 103 had COPD. Patients with only SABA prescriptions were less likely to be hospitalized (aOR, .59; 104 95% CI, .43-.8; P <.001). Male sex, Asian race, COPD, and SABA-only remained significant 105 after correcting for multiple comparisons (bolded aORs in Table 2) . 106

While obesity, chronic kidney disease, and marital status were significantly associated 107 with increased risk of ICU admission compared to general inpatient hospitalization they were not 108 robust to Bonferroni correction. Similarly, cardiovascular disease (aOR 2.21; 95% CI, 1.21 to 109 4.04; P <.01) and male sex were the only variables that predicted higher odds of mortality but 110 did not meet the significance threshold for multiple testing. 111

Several hospitalization risk factors for patients with asthma and COVID-19 reflect those 112 identified in general populations of COVID-19 patients, including male sex, race, older age, and 113 non-respiratory comorbidities. Notably, male sex was a risk factor despite female predominance 114 in COVID-19 testing and in positive diagnosis among asthma patients. 115

In distinguishing asthma within chronic respiratory disease categorization, we found that 116 a co-morbid diagnosis of COPD was a strong risk factor for hospitalization, and the only 117 comorbidity that remained statistically significant after correction for multiple comparisons. Mild 118 asthma managed with SABA alone, was more common in patients triaged to outpatient care 119 and these patients were less likely to be hospitalized. In contrast, we found no differences in risk for hospitalization or ICU-level care with ICS or combined ICS-LABA use. Asthma-specific 121 variables did not predict ICU care or mortality and the differences between risk for inpatient 122 hospitalization and ICU admission is a compelling area for future investigation. 123

MGB health system serves the largest volume of hospitalized COVID-19 patients in New 124

England. However, despite having an MGB PCP some patients may have sought COVID-19 125 care out of our hospital system. Asthma prevalence in MGB COVID-19 positive patients (13.1%) 126 is within range of chronic respiratory disease and/or COPD (4.6%-15.6%) rates from China 127 COVID-19 studies 4,5,9 and slightly higher than the asthma prevalence in a large New York City 128 cohort (9%) 7 . EHR prescription data is not linked to pharmacy fill data; future research could use 129 administrative claims data to strengthen associations with baseline asthma medication use. 130

Finally, a small number of patients remained hospitalized at the time of censoring, which may 131 have led to underreporting of subsequent ICU admissions or deaths. Available data supports 132 that mortality was similar for asthma and non-asthma COVID-19 patients in the MGB outpatient 133 and inpatient setting. 

Chronic kidney disease

SABA-anticholinergic combination 106/1827 (5.8)